SC
SUPN icon

Steven Cohen’s Supernus Pharmaceuticals SUPN Stock Holding History

Steven Cohen’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-58,900
Closed -$2.97M – 1190
2018
Q3 		$2.97M Sell
58,900
-291,100
-83% -$14.4M 0.01% 694
2018
Q2 		$20.9M Buy
+350,000
New +$18.1M 0.08% 292

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Steven Cohen's SUPN Position: Q2 2026 in Review

Steven Cohen sold out of Supernus Pharmaceuticals (SUPN) in Q2 2026, closing a stake of 1,318,555 shares — an estimated $68.2M sold.

Steven Cohen first reported a position in SUPN in Q1 2016 and held it in 13 quarters. The position peaked at $113M in Q4 2025. 331 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Steven Cohen reported no remaining Supernus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Steven Cohen sold 1,318,555 Supernus Pharmaceuticals shares in Q2 2026, an estimated $68.2M.
  • Steven Cohen first reported a position in Supernus Pharmaceuticals in Q1 2016 and held it in 13 quarters.
  • Steven Cohen's Supernus Pharmaceuticals position peaked at $113M in Q4 2025.
  • 331 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.